HSBC Holdings’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.3M | Buy |
184,222
+115,930
| +170% | +$15.4M | 0.01% | 689 |
|
|
2025
Q4 | $9.68M | Sell |
68,292
-115,365
| -63% | -$16.7M | ﹤0.01% | 967 |
|
|
2025
Q3 | $25.8M | Sell |
183,657
-5,580
| -3% | -$756K | 0.01% | 644 |
|
|
2025
Q2 | $23.8M | Sell |
189,237
-53,798
| -22% | -$6.17M | 0.01% | 657 |
|
|
2025
Q1 | $26.9M | Buy |
243,035
+30,681
| +14% | +$3.89M | 0.02% | 634 |
|
|
2024
Q4 | $29M | Sell |
212,354
-10,904
| -5% | -$1.35M | 0.02% | 632 |
|
|
2024
Q3 | $25.7M | Buy |
223,258
+110,185
| +97% | +$15.1M | 0.01% | 661 |
|
|
2024
Q2 | $15.6M | Sell |
113,073
-26,793
| -19% | -$3.67M | 0.01% | 744 |
|
|
2024
Q1 | $19.3M | Buy |
139,866
+35,910
| +35% | +$4.9M | 0.01% | 709 |
|
|
2023
Q4 | $13.7M | Buy |
103,956
+25,975
| +33% | +$2.99M | 0.01% | 781 |
|
|
2023
Q3 | $8.78M | Buy |
77,981
+1,012
| +1% | +$107K | 0.01% | 874 |
|
|
2023
Q2 | $7.26M | Sell |
76,969
-37,946
| -33% | -$3.71M | 0.01% | 924 |
|
|
2023
Q1 | $11.6M | Buy |
114,915
+36,616
| +47% | +$3.81M | 0.01% | 791 |
|
|
2022
Q4 | $9.35M | Buy |
78,299
+10,291
| +15% | +$1.21M | 0.01% | 992 |
|
|
2022
Q3 | $7.22M | Buy |
68,008
+9,334
| +16% | +$947K | 0.01% | 1032 |
|
|
2022
Q2 | $5.72M | Buy |
58,674
+518
| +0.9% | +$47.8K | 0.01% | 1142 |
|
|
2022
Q1 | $5.45M | Buy |
58,156
+4,781
| +9% | +$405K | 0.01% | 1155 |
|
|
2021
Q4 | $4.55M | Buy |
53,375
+8,975
| +20% | +$826K | ﹤0.01% | 1309 |
|
|
2021
Q3 | $4.26M | Buy |
44,400
+13,817
| +45% | +$1.31M | ﹤0.01% | 1207 |
|
|
2021
Q2 | $2.99M | Buy |
30,583
+20,357
| +199% | +$1.95M | ﹤0.01% | 1287 |
|
|
2021
Q1 | $993K | Sell |
10,226
-6,190
| -38% | -$649K | ﹤0.01% | 1608 |
|
|
2020
Q4 | $1.58M | Buy |
16,416
+1,379
| +9% | +$133K | ﹤0.01% | 1437 |
|
|
2020
Q3 | $1.45M | Sell |
15,037
-3,540
| -19% | -$409K | ﹤0.01% | 1392 |
|
|
2020
Q2 | $2.27M | Buy |
18,577
+11,975
| +181% | +$1.32M | ﹤0.01% | 1133 |
|
|
2020
Q1 | $572K | Sell |
6,602
-8,090
| -55% | -$792K | ﹤0.01% | 1720 |
|
|
2019
Q4 | $1.58M | Sell |
14,692
-4,039
| -22% | -$423K | ﹤0.01% | 1602 |
|
|
2019
Q3 | $1.69M | Buy |
18,731
+5,250
| +39% | +$490K | ﹤0.01% | 1684 |
|
|
2019
Q2 | $1.14M | Buy |
13,481
+3,486
| +35% | +$286K | ﹤0.01% | 1728 |
|
|
2019
Q1 | $880K | Sell |
9,995
-137,106
| -93% | -$11.5M | ﹤0.01% | 1877 |
|
|
2018
Q4 | $10.5M | Buy |
147,101
+131,592
| +848% | +$12.6M | 0.02% | 796 |
|
|
2018
Q3 | $1.9M | Buy |
+15,509
| New | +$1.76M | ﹤0.01% | 1489 |
|
|
2018
Q1 | – | Sell |
-5,765
| Closed | -$447K | – | 2580 |
|
|
2017
Q4 | $447K | Buy |
+5,765
| New | +$393K | ﹤0.01% | 1548 |
|
Other funds holding NBIX
VPM
VCM
HSBC Holdings's NBIX Position: Q1 2026 in Review
HSBC Holdings increased its Neurocrine Biosciences (NBIX) stake by 170% in Q1 2026, buying an estimated $15.4M and bringing the position to 184,222 shares worth $24.3M. The position accounts for 0.01% of the portfolio, ranked #689.
HSBC Holdings first reported a position in NBIX in Q4 2017 and has held it in 32 quarters since. The position peaked at $29M in Q4 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- HSBC Holdings held 184,222 shares of Neurocrine Biosciences worth $24.3M as of Q1 2026.
- HSBC Holdings bought 115,930 Neurocrine Biosciences shares in Q1 2026, an estimated $15.4M.
- Neurocrine Biosciences made up 0.01% of HSBC Holdings's portfolio in Q1 2026, its #689 holding.
- HSBC Holdings first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 32 quarters since.
- HSBC Holdings's Neurocrine Biosciences position peaked at $29M in Q4 2024.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.